Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. 1996

M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
Department of Dermatology, University Hospital of Aarhus, Denmark.

The monocyte chemotactic protein-1 (MCAF) also termed MCP-1, a strong chemotactic factor towards monocytes, is produced by several cell types present in the skin. The in situ presence of MCAF/MCP-1 protein in the skin has, however, not yet been established. Using immunohistochemical techniques we have investigated the distribution of MCAF in skin from patients with different types of psoriasis and normal healthy volunteers. We report the novel finding that psoriasis has strong positive immunostaining for MCAF located to all the layers of the epidermis, except the stratum granulosum, in pustular, guttate and chronic plaque psoriasis. In the dermis, infiltrating cells in the perivascular aggregates and the blood vessels stained positive for MCAF. No significant differences were observed between the different subtypes of psoriasis except that strongly positive infiltrating cells were observed in the epidermal pustules in pustular psoriasis. In normals positive staining was observed in all the layers of the epidermis and in a few perivascular cells and blood vessels in the dermis. Where present in normal and diseased skin, eccrine ducts of sweat glands and sebaceous glands stained positive for MCAF. Arrector pili muscles were in all cases negative. These findings are consistent with a role for MCAF in attracting inflammatory cells, including monocytes, into the skin in psoriasis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D018932 Chemokine CCL2 A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS. Monocyte Chemoattractant Protein-1,Monocyte Chemotactic Protein-1,CCL2 Chemokine,Chemokine (C-C Motif) Ligand 2,Chemokines CCL2,Monocyte Chemotactic and Activating Factor,CCL2, Chemokine,CCL2, Chemokines,Chemoattractant Protein-1, Monocyte,Chemokine, CCL2,Chemotactic Protein-1, Monocyte,Monocyte Chemoattractant Protein 1,Monocyte Chemotactic Protein 1

Related Publications

M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
October 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
October 1999, Nihon Jinzo Gakkai shi,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
April 1990, International journal of cancer,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
May 1997, Journal of dermatological science,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
January 1997, Journal of investigational allergology & clinical immunology,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
March 1998, Cytokine & growth factor reviews,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
February 1989, Biochemical and biophysical research communications,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
September 1993, Cytokine,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
June 1990, The Journal of experimental medicine,
M Deleuran, and L Buhl, and T Ellingsen, and A Harada, and C G Larsen, and K Matsushima, and B Deleuran
May 1989, Biochemical and biophysical research communications,
Copied contents to your clipboard!